Overweight and obesity managementStatus:In development | In consultationConsultation end date: 15 April 2025Expected publication date: 5 August 2025
Semaglutide for managing overweight and obesity and the reduction of associated cardiovascular risk (ID6441 including a review of TA875 and TA910)Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC